Enlicitide is a macrocyclic peptide — a ring-shaped molecule designed to achieve biologic-like target specificity in an orally administered form. For years, oral delivery of peptide drugs has been a major pharmaceutical challenge. Enlicitide represents a meaningful advance.

It binds directly to PCSK9, blocking its interaction with LDL receptors on hepatocyte surfaces and preventing receptor degradation — the same target as evolocumab and alirocumab, but in a once-daily tablet.

The ~28% median Lp(a) reduction is clinically significant. For patients who already know they have raised Lp(a) and have been waiting for an oral option — this is worth knowing about, even though UK and EU availability is not yet confirmed.

A daily tablet removes injection aversion — but reintroduces daily adherence as a determinant of efficacy. Injectables have near-perfect persistence once administered. Daily tablets do not. Empty stomach, 30 minutes before food, every morning — that matters.

LIPFENDRA lists at ~$315/month — roughly half the list price of injectable PCSK9 inhibitors, and without the administration costs of clinician-delivered therapies like inclisiran. But list price is not what patients pay. Prior authorisation and formulary positioning versus injectable PCSK9 antibodies, ezetimibe, and bempedoic acid will determine real-world access.